CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,672,192 | -65.6% | 971 | -99.6% | 0.32% | -81.8% |
Q1 2023 | $7,773,732 | -34.8% | 216,057 | -19.2% | 1.76% | -38.7% |
Q4 2022 | $11,921,406 | +33.6% | 267,476 | -15.7% | 2.88% | +61.8% |
Q3 2022 | $8,924,000 | -80.1% | 317,476 | -80.9% | 1.78% | -78.2% |
Q2 2022 | $44,788,000 | -11.0% | 1,661,158 | +12.4% | 8.17% | +23.4% |
Q1 2022 | $50,323,000 | -11.1% | 1,477,558 | +0.9% | 6.62% | -21.5% |
Q4 2021 | $56,577,000 | -33.8% | 1,464,216 | -7.5% | 8.43% | +40.1% |
Q3 2021 | $85,425,000 | +160.3% | 1,582,231 | +61.2% | 6.02% | +126.8% |
Q2 2021 | $32,824,000 | +44.9% | 981,544 | -10.8% | 2.65% | +248.2% |
Q1 2021 | $22,657,000 | -26.7% | 1,099,790 | -37.7% | 0.76% | -44.1% |
Q4 2020 | $30,923,000 | +36.0% | 1,764,990 | +15.1% | 1.36% | -17.1% |
Q3 2020 | $22,742,000 | -9.0% | 1,533,530 | -20.2% | 1.64% | -17.3% |
Q2 2020 | $24,986,000 | – | 1,921,939 | – | 1.99% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |